Stock Traders Buy Large Volume of Call Options on OPKO Health (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 5,038 call options on the stock. This is an increase of 101% compared to the average volume of 2,501 call options.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 47,537 shares of the stock in a transaction dated Tuesday, January 28th. The stock was bought at an average cost of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the purchase, the chief executive officer now owns 213,234,014 shares in the company, valued at $313,454,000.58. This represents a 0.02 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders have bought 814,971 shares of company stock valued at $1,308,192. 49.69% of the stock is currently owned by insiders.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 11,089 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of OPKO Health in the 3rd quarter valued at approximately $201,000. XTX Topco Ltd increased its stake in OPKO Health by 166.5% during the 3rd quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company's stock worth $162,000 after purchasing an additional 67,883 shares in the last quarter. Orion Portfolio Solutions LLC acquired a new stake in OPKO Health during the 3rd quarter worth approximately $45,000. Finally, Barclays PLC lifted its stake in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after buying an additional 329,870 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th.

OPKO Health Price Performance

NASDAQ OPK remained flat at $1.42 on Friday. The company had a trading volume of 2,160,919 shares, compared to its average volume of 3,921,262. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health has a fifty-two week low of $1.15 and a fifty-two week high of $2.04. The company has a market capitalization of $953.60 million, a PE ratio of -7.47 and a beta of 1.78. The company has a 50 day moving average of $1.67 and a 200 day moving average of $1.57.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, analysts forecast that OPKO Health will post -0.25 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.